Deerfield Management Company »

Prelude Therapeutics shares owned by Deerfield Management Company

Quarter-by-quarter ownership of Prelude Therapeutics (PRLD) shares owned by Deerfield Management Company from 13F filings

Historical chart of Deerfield Management Company investment in Prelude Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Prelude Therapeutics held by Deerfield Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prelude Therapeutics by Deerfield Management Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $18M 4.1M 4.27

More positions owned by Deerfield Management Company

Nuvalent Inc-a (NUVL)
Glaukos Corp Note 2.750% 6/1 (Principal)
Viatris (VTRS)
Invitae Corp Debt 4.500% 3/1 (Principal)
Natera Note 2.250% 5/0 (Principal)
Catalyst Pharmaceutical Partners (CPRX)
Centene Corporation (CNC)
Brookdale Sr Living Note 2.000%10/1 (Principal)
Insmed Note 1.750% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Accolade Note 0.500% 4/0 (Principal)
Oscar Health Cl A (OSCR)
Owens & Minor (OMI)
Adapthealth Corp Common Stock (AHCO)
Springworks Therapeutics (SWTX)

View all positions for Deerfield Management Company

Top funds holding Prelude Therapeutics

OrbiMed Advisors
Baker Bros. Advisors
Deerfield Management Company
Boxer Capital
T. Rowe Price Associates
Vanguard Group
Massachusetts Financial Services
TD Asset Management
Jacobs Levy Equity Management
Charles Schwab Investment Management
Citadel Advisors
Millennium Management
Goldman Sachs Group
Exchange Traded Concepts
Two Sigma Advisers

View all funds holding Prelude Therapeutics